Stephanie Nimmo, NP
Family · Springfield, MONPI 1457881716
Payments from drug & device makers
Across 18 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$112
- Sanofi$75
- Lilly USA, LLC$63
- ANI Pharmaceuticals, Inc.$45
- UCB, Inc.$42
- AbbVie$31
- plus $117 from 7 others
What the payments were for
- Food & beverage$483100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $112 |
| Sanofi | 1 | $75 |
| Lilly USA, LLC | 3 | $63 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| UCB, Inc. | 2 | $42 |
| AbbVie | 2 | $31 |
| AstraZeneca | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Coloplast | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Argenx US, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$484 in reported general payments places this provider in the 50th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 114 | $57,673 |
| Tamsulosin Hcl | 565 | $9,242 |
| Trospium Chloride | 110 | $4,908 |
| Tolterodine Tartrate | 42 | $4,800 |
| Methenamine Hippurate | 78 | $3,158 |
| Oxybutynin Chloride ErOxybutynin Chloride | 218 | $2,684 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $2,501 |
| Finasteride | 371 | $2,444 |
| Solifenacin Succinate | 58 | $1,778 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 20 | $1,330 |
| Oxybutynin Chloride | 75 | $944 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 81 | $772 |
| Doxazosin Mesylate | 48 | $691 |
| Cephalexin | 59 | $495 |
| Tadalafil | 14 | $482 |
Paid to pharmacies, not to this prescriber.
Other family in Springfield
- Laura HedigerSpringfield$71K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.